Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival.

Few molecular genetic alterations have been identified in endometrial cancers that are associated with poor clinical outcome. Overexpression of HER-2/neu, transforming growth factor alpha, and p53 proteins have all been associated with poor prognosis in women with endometrial cancer. In this study, the level of HER-2/neu gene amplification and expression was characterized in 92 endometrial cancers. Fluorescence in situ hybridization (FISH) was used to characterize HER-2/neu gene copy number, and immunohistochemistry was used to characterize expression. Forty-seven of the 90 (52%) endometrial cancers were characterized as showing moderate or high immunostaining. HER-2/neu gene amplification was detected in 17 of 81 (21%) cases. Immunohistochemical staining and FISH results were both available for 80 cases. Fourteen of these cases showed both moderate or high immunostaining and gene amplification. Clinical follow-up information was available for 76 women in this study. Women whose endometrial cancer exhibited HER-2/neu gene amplification by FISH had a shorter overall survival than women whose endometrial cancer lacked amplification (P = 0.018). Likewise, tumors with moderate or high HER-2/neu immunostaining were associated with a lower cumulative overall survival than tumors with low immunostaining by log rank analysis (P < 0.0001). Multivariate analysis of survival rates revealed HER-2/neu overexpression to be an independent predictor of overall survival (P = 0.0163). Among those patients with HER-2/neu overexpression, adjuvant chemotherapy or radiation therapy was associated with an improved overall survival (P = 0.039). However, among those women whose tumor lacked overexpression, overall survival was not improved by adjuvant treatment.

[1]  B. Karlan,et al.  HER‐2/neu, p53, and DNA Analyses as Prognosticators for Survival in Endometrial Carcinoma , 1995, Obstetrics and gynecology.

[2]  M. Pike,et al.  Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. , 1994, Cancer research.

[3]  G. Niehans,et al.  Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival. , 1994, Human pathology.

[4]  D. Shibata,et al.  Microsatellite instability in sporadic endometrial carcinoma. , 1994, Journal of the National Cancer Institute.

[5]  W. Dougall,et al.  The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies. , 1994, Oncogene.

[6]  R. Chaganti,et al.  Genetic changes in epithelial solid neoplasia. , 1994, Cancer research.

[7]  R. Bast,et al.  Multivariable analysis of DNA ploidy, p53, and HER‐2/neu as prognostic factors in endometrial cancer , 1994, Cancer.

[8]  D. Shibata,et al.  Early mutational activation of the c-Ki-ras oncogene in endometrial carcinoma. , 1994, Cancer research.

[9]  Yusuke Nakamura,et al.  Allelotype of uterine cancer by analysis of RFLP and microsatellite polymorphisms: Frequent loss of heterozygosity on chromosome arms 3p, 9q, 10q, and 17p , 1994, Genes, chromosomes & cancer.

[10]  I. Konishi,et al.  Expression of c‐erbb‐2 protein and epidermal growth factor receptor in endometrial carcinomas correlation with clinicopathologic and sex steroid receptor status , 1993, Cancer.

[11]  S. Cha,et al.  HER‐2/neu expression: A major prognostic factor in endometrial cancer , 1992, Gynecologic oncology.

[12]  P. Humphrey,et al.  Overexpression and mutation of p53 in endometrial carcinoma. , 1992, Cancer research.

[13]  G. Sutton,et al.  Immunohistochemical Study of HER-2/neu, Epidermal Growth Factor Receptor, and Steroid Receptor Expression in Normal and Malignant Endometrium , 1992, Obstetrics and gynecology.

[14]  D. Clarke-Pearson,et al.  Overexpression of HER‐2/neu in endometrial cancer is associated with advanced stage disease , 1991, American journal of obstetrics and gynecology.

[15]  H. Sasano,et al.  Expression of c-myc, epidermal growth factor receptor and c-erbB-2 in human endometrial carcinoma and cervical adenocarcinoma. , 1991, The Tohoku journal of experimental medicine.

[16]  K. Hatch,et al.  Oncogene alterations in endometrial carcinoma. , 1990, Gynecologic oncology.

[17]  M. Cauchi,et al.  Point mutations at codon 12 of C-K-ras in human endometrial carcinomas. , 1990, Cancer letters.

[18]  G. Hortobagyi,et al.  c-erbB-2 amplification in node-negative human breast cancer. , 1989, Cancer research.

[19]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[20]  A. Ullrich,et al.  Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[21]  P. Seeburg,et al.  Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. , 1985, Science.

[22]  K. Semba,et al.  A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[23]  J. Minna,et al.  Immunohistochemical localization of the immunodominant differentiation antigen lacto-N-fucopentaose III in normal adult and fetal tissues. , 1984, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[24]  N. Breslow.  Covariance analysis of censored survival data. , 1974, Biometrics.

[25]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[26]  P. Wingo,et al.  Cancer statistics, 1995 , 1995, CA: a cancer journal for clinicians.

[27]  S. Nasim,et al.  Prognostic significance of p53 overexpression in endometrial cancer. , 1994, Cancer research.

[28]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[29]  A. Coldman,et al.  Examining survival data. , 1979, Canadian Medical Association journal.

[30]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .